ulcerative


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

ul·cer·ate

 (ŭl′sə-rāt′)
v. ul·cer·at·ed, ul·cer·at·ing, ul·cer·ates
v.intr.
To develop an ulcer; become ulcerous.
v.tr.
To cause ulceration of.

ul′cer·a′tive (-sə-rā′tĭv, -sər-ə-tĭv) adj.

ulcerative

(ˈʌlsərətɪv)
adj
(Pathology) of, relating to, or characterized by ulceration: ulcerative colitis.

ul•cer•a•tive

(ˈʌl səˌreɪ tɪv, -sər ə tɪv)

adj.
1. causing ulceration.
2. of the nature of or affected with ulceration.
[1565–75; < Medieval Latin]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Adj.1.ulcerative - of or relating to or characterized by ulceration; "ulcerative colitis"
Translations

ul·cer·a·tive

a. ulcerativo-a, rel. a una úlcera o caracterizado-a por una condición ulcerosa;
___ colitiscolitis ___.
References in periodicals archive ?
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
ENPNewswire-August 28, 2019--InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis
FRIDAY, July 26, 2019 (HealthDay News) -- New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib (Xeljanz, Xeljanz XR) have been issued by the U.S.
INFLAMMATORY bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease.
Global Banking News-June 26, 2019-InDex Pharmaceuticals admits last patient in Phase IIb Study CONDUCT evaluating cobitolimod for ulcerative colitis
M2 PHARMA-June 26, 2019-InDex Pharmaceuticals admits last patient in Phase IIb Study CONDUCT evaluating cobitolimod for ulcerative colitis
M2 EQUITYBITES-June 26, 2019-InDex Pharmaceuticals admits last patient in Phase IIb Study CONDUCT evaluating cobitolimod for ulcerative colitis
The investigators retrospectively studied 3,517 individuals with Crohn's disease and 5,349 patients with ulcerative colitis from ResearchOne, a primary care electronic health records database that covers about 10% of patients in England.
Among patients with moderate to severe ulcerative colitis, a median of 1.4 years and up to 4.4 years of tofacitinib therapy was safe apart from a dose-related increase in risk of herpes zoster infection, according to an integrated analysis of data from five clinical trials.
[USA], May 9 (ANI): A recent study has revealed that individuals who suffered from inflammatory bowel disease including ulcerative colitis and Crohn's disease during childhood are at an increased risk of cancer and early death.